ADMA Biologics Inc $ADMA Shares Bought by B Group Inc.
B Group Inc. grew its stake in ADMA Biologics Inc (NASDAQ: ADMA) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,412,542 shares of the biotechnology company's stock after purchasing an additional 95,000 shares during the quarter. ADMA Biologics
Why the Market Dipped But Adma Biologics (ADMA) Gained Today
Adma Biologics (ADMA) concluded the recent trading session at $15.15, signifying a +1.03% move from its prior day's close.
4 Biotech Stocks to Watch for Potential Upside in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Adma Biologics (ADMA) reached $14.99 at the closing of the latest trading day, reflecting a -4.34% change compared to its last close.
Best Momentum Stocks to Buy for March 12th
ADMA, RELY and HSY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 12th, 2026.
New Strong Buy Stocks for March 12th
AEO, RELY, ADMA, HSY and HTBK have been added to the Zacks Rank #1 (Strong Buy) List on March 12th, 2026.
Adma Biologics (ADMA) Upgraded to Strong Buy: Here's Why
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance
ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.
ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Adma Biologics (ADMA) closed the most recent trading day at $16.32, moving +2.06% from the previous trading session.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Adma Biologics (ADMA) closed at $15.59 in the latest trading session, marking a -4.24% move from the prior day.
